Under construction – not a live service
Sign in
Taking people in United StatesPhase 3

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Key facts

Where
Anaheim, Atlanta, Auburn, Boston, Brandon, Cerritos, Chandler, Charleston, Chesterfield, Chicago, Chula Vista, Cincinnati, Colorado Springs, Columbia, Cullman, Denver, Fayetteville, Henderson, Hialeah, Houston, Huntersville, Huntington Beach, Kenner, Lansing, Little Rock, Long Beach, Miami, Miami Lakes, Middletown, Novi, San Antonio, Santa Ana, Southfield, Spokane, St Louis, Stockbridge, Sugar Land, Towson, Tucson, and Wyomissing, United StatesSee the 40 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT06568367, who can take part

Where in United States

  • Anaheim, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Auburn, AlabamaHospital not named in the registryContact: Study DirectorTaking people
  • Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Brandon, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Cerritos, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Chandler, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Chesterfield, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Study DirectorTaking people
  • Chula Vista, CaliforniaHospital not named in the registryContact: Study DirectorNo longer taking part
  • Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
  • Colorado Springs, ColoradoHospital not named in the registryContact: Study DirectorTaking people
  • Columbia, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Cullman, AlabamaHospital not named in the registryContact: Study DirectorTaking people
  • Denver, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Fayetteville, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Henderson, NevadaHospital not named in the registryContact: Study DirectorTaking people
  • Hialeah, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Huntersville, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Huntington Beach, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Kenner, LouisianaHospital not named in the registryContact: Study DirectorTaking people
  • Lansing, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Little Rock, ArkansasHospital not named in the registryContact: Study DirectorTaking people
  • Long Beach, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Miami Lakes, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Middletown, New JerseyHospital not named in the registryContact: Study DirectorTaking people
  • Novi, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • San Antonio, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Southfield, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Spokane, WashingtonHospital not named in the registryContact: Study DirectorTaking people
  • St Louis, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • Stockbridge, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Sugar Land, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Towson, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Tucson, ArizonaHospital not named in the registryContact: Study DirectorNo longer taking part
  • Wyomissing, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Axsome Therapeutics, Inc.
Trial code
NCT06568367
Record updated
24 July 2026
Original description
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).Read full original descriptionShow less

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Inclusion: Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD); Provides written informed consent to participate in the study before the conduct of any study procedures; Male or female, aged 18 to 65 inclusive.

Exclusion: Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription; Unable to comply with study procedures; Medically inappropriate for study participation in the opinion of the investigator.

ClinicalTrials.gov NCT06568367